Armata Pharmaceuticals, Inc.
ARMP- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000921114
No open-market purchases or sales by Armata Pharmaceuticals, Inc. insiders were filed in the last 90 days; 53 institutions reported holding it in 13F filings for Q2 2026, worth $32.3M in total; no superinvestor holds it.
13F holders, Q4 2023
Institutional positions in Armata Pharmaceuticals, Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +2 vs. Q3 2023
- Shares held
- 1.29M
- +7.01K (+0.5%) vs. Q3 2023
- Total value
- $4.17M
- +$328.5K (+8.5%) vs. Q3 2023
- New holders
- 3
- 5 more added
- Sold out
- 1
- 5 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ARMP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 53 | $32.3M |
| Q1 2026 | 45 | $40.2M |
| Q4 2025 | 36 | $7.85M |
| Q3 2025 | 28 | $2.27M |
| Q2 2025 | 29 | $1.40M |
| Q1 2025 | 26 | $1.08M |
| Q4 2024 | 24 | $2.57M |
| Q3 2024 | 24 | $3.28M |
| Q2 2024 | 23 | $3.86M |
| Q1 2024 | 24 | $5.93M |
| Q4 2023 | 25 | $4.17M |
| Q3 2023 | 23 | $3.85M |
| Q2 2023 | 22 | $1.35M |
| Q1 2023 | 23 | $2.06M |
| Q4 2022 | 26 | $1.61M |
| Q3 2022 | 20 | $5.73M |
| Q2 2022 | 19 | $5.25M |
| Q1 2022 | 20 | $6.61M |
| Q4 2021 | 17 | $7.25M |
| Q3 2021 | 20 | $4.32M |
| Q2 2021 | 21 | $4.59M |
| Q1 2021 | 23 | $5.62M |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding Armata Pharmaceuticals, Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 634,451 | $2.06M | 0.00% | +70.0% | Added |
| Vanguard Group Inc | 145,078 | $470.1K | 0.00% | +54,109+59.5% | Added |
| Bridgeway Capital Management, LLC | 110,382 | $357.6K | 0.01% | −50,000−31.2% | Reduced |
| Geode Capital Management, LLC | 101,013 | $327.4K | 0.00% | 00.0% | Unchanged |
| Edgewood Management LLC | 100,000 | $324.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 53,596 | $174.0K | 0.00% | −3,900−6.8% | Reduced |
| State Street Corp | 40,300 | $130.6K | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 23,563 | $76.3K | 0.00% | +21,372+975.4% | Added |
| BlackRock Inc. | 22,760 | $73.7K | 0.00% | −266−1.2% | Reduced |
| Northern Trust Corp | 19,380 | $62.8K | 0.00% | 00.0% | Unchanged |
| SeaCrest Wealth Management, LLC | 18,130 | $56.4K | 0.01% | 00.0% | Unchanged |
| Captrust Financial Advisors | 13,548 | $43.9K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 3,367 | $10.9K | 0.00% | −2,210−39.6% | Reduced |
| Larson Financial Group LLC | 967 | $3.13K | 0.00% | +967 | New |
| Trifecta Capital Advisors, LLC | 714 | $2.31K | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 571 | $1.85K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 282 | $1.00K | 0.00% | +264+1,466.7% | Added |
| Tennessee Valley Asset Management Partners | 279 | $904 | 0.00% | +279 | New |
| JPMorgan Chase & Co | 105 | $340 | 0.00% | +105 | New |
| Salem Investment Counselors Inc | 100 | $324 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 84 | $271 | 0.00% | +4+5.0% | Added |
| Team Financial Group, LLC | 71 | $230 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 2 | $6 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 1 | $3 | 0.00% | −2,248−100.0% | Reduced |
| Householder Group Estate & Retirement Specialist, LLC | 136 | $0 | 0.00% | 00.0% | Unchanged |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −11,472−100.0% | Sold out |